Stockreport

Gain Therapeutics Announces Presentations at AD/PDTM 2026 and Provides U.S. FDA Regulatory Update [Yahoo! Finance]

Gain Therapeutics, Inc.  (GANX) 
PDF Gain Therapeutics, Inc. Interim analysis of Phase 1b clinical study of GT-02287, including biomarker and clinical endpoints, will be presented in oral symposium Com [Read more]